EpiPen’s flying solo

The climb in price for the EpiPen product is a result of the lack of competition in the drug and medical market. If there were more alternatives, then Mylan would not be able to raise the price so easily.

Our leaders should be calling for and submitting legislation to make the drug market more competitive and make sure that consumers have alternatives. We should push the four presidential candidates to make deregulation of the drug market an integral part of their campaigns. Gary Houck Orlando